BeiGene
BGNE
#881
Rank
ยฃ16.89 B
Marketcap
ยฃ153.91
Share price
1.71%
Change (1 day)
-1.81%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Cash on Hand

Cash on Hand as of June 2024 : ยฃ1.97 B

According to BeiGene 's latest financial reports the company has ยฃ1.97 B in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31ยฃ2.49 B-33.53%
2022-12-31ยฃ3.74 B-23.34%
2021-12-31ยฃ4.88 B43.53%
2020-12-31ยฃ3.40 B360.02%
2019-12-31ยฃ0.74 B-46.96%
2018-12-31ยฃ1.39 B125.3%
2017-12-31ยฃ0.61 B107.68%
2016-12-31ยฃ0.29 B340.5%
2015-12-31ยฃ67.73 M137.52%
2014-12-31ยฃ28.51 M1099.64%
2013-12-31ยฃ2.37 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
ยฃ12.48 M-99.37%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ30.91 M-98.43%๐Ÿ‡บ๐Ÿ‡ธ USA